Recent Updates
Recently added Catalysts
SEER Positive Sentiment

Seer to Participate in Upcoming November Investor Conferences

Key Takeaway: Seer, Inc. announced its participation in several investor conferences scheduled for November. The company, known for its advancements in proteomics, will provide live webcasts of the sessions on its investor website. Seer's Proteograph Product Suite is noted for delivering unmatched proteomic insights, emphasizing the company's leadership in the field.
Price reaction · baseline $2.22 (2025-10-29 close) · hit after-hours · clean, no other SEER news in the window
day 0 close
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is participating in multiple investor conferences, showcasing its engagement.
  • The company highlights its innovative Proteograph Product Suite, which sets industry standards.
  • Live webcasts and archived replays enhance accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~65 mo
Minimal dilution risk
Lead asset
standardized turmeric root extract
Phase 1 · Cystic Fibrosis

Full Press Release Details

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences:
Live webcasts of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference.
About SeerSeer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visitwww.seer.bio.

Media Contact:Patrick Schmidtpr@seer.bio

Investor Contact:Carrie Mendivilinvestor@seer.bio

Frequently Asked Questions

What investor conferences is Seer participating in?

Seer is participating in several investor conferences scheduled for November.

Where can I watch Seer's conference sessions?

Live webcasts of Seer's sessions will be available on their investor website.

What is Seer's Proteograph Product Suite?

Seer's Proteograph Product Suite delivers deep, unbiased proteomic insights.

Are Seer's products intended for diagnostic use?

No, Seer's products are for research use only and not for diagnostic procedures.

Last updated: Oct 29, 2025